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These guidelines are intended for use by infectious disease specialists, orthopedists, and other healthcare
professionals who care for patients with prosthetic joint infection (PJI). They include evidence-based and
opinion-based recommendations for the diagnosis and management of patients with PJI treated with
debridement and retention of the prosthesis, resection arthroplasty with or without subsequent staged
reimplantation, 1-stage reimplantation, and amputation.
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EXECUTIVE SUMMARY
Background
Joint replacement is a highly effective intervention
that signiﬁcantly improves patients’ quality of life, pro-
viding symptom relief, restoration of joint function,
improved mobility, and independence. Prosthetic joint
infection (PJI) remains one of the most serious com-
plications of prosthetic joint implantation. The man-
agement of PJI almost always necessitates the need for
surgical intervention and prolonged courses of intrave-
nous or oral antimicrobial therapy [1–4]. Despite a sig-
niﬁcant amount of basic and clinical research in this
ﬁeld, many questions pertaining to the deﬁnition of in-
fection as well as diagnosis and management of these
infections remain unanswered. The focus of these
guidelines is to provide a consensus statement that ad-
dresses the diagnosis and the medical and surgical
treatment of infections involving a prosthetic joint. In
many situations, the panel has made recommendations
based on expert opinion, realizing that the amount of
data to support a speciﬁc recommendation is limited
and that there are diverse practice patterns which seem
to be equally effective for a given clinical problem.
An essential component of the care of patients with
PJI is strong collaboration between all involved
medical and surgical specialists (eg, orthopedic sur-
geons, plastic surgeons, infectious disease specialists,
internists). It is anticipated that consideration of these
guidelines may help reduce morbidity, mortality, and
the costs associated with PJI. The panel realizes that
not all medical institutions will have the necessary
resources to implement all the recommendations in
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these guidelines. Proper referral to specialty centers may need
to occur.
Each section of the guideline begins with a speciﬁc clinical
question and is followed by numbered recommendations and
a summary of the most relevant evidence in support of the
recommendations. The panel followed a process used in the
development of other Infectious Diseases Society of America
(IDSA) guidelines, which included a systematic weighting of
the quality of the evidence and the grade of recommendation [5]
(Table 1). A detailed description of the methods, background,
and evidence summaries that support each of the recommen-
dations can be found in the full text of the guideline. Areas of
controversy in which data are limited or conﬂicting and where
additional research is needed are indicated throughout the
document and are highlighted in the “Research Gaps” section
in the full text of the guideline.
I. What preoperative evaluation and intraoperative testing
should be performed to diagnose PJI and what is the deﬁnition
of PJI?
Recommendations
Preoperative Evaluation (Figure 1)
1. Suspect PJI in patients with any of the following (B-III):
A sinus tract or persistent wound drainage over a joint pros-
thesis, acute onset of a painful prosthesis, or any chronic
painful prosthesis at any time after prosthesis implantation,
particularly in the absence of a pain-free interval, in the ﬁrst
few years following implantation or if there is a history of
prior wound healing problems or superﬁcial or deep infection.
2. Evaluation of the patient with a possible PJI should
include a thorough history and physical examination (C-III).
Items that should be obtained in the history include the type
of prosthesis, date of implantation, past surgeries on the joint,
history of wound healing problems following prosthesis im-
plantation, remote infections, current clinical symptoms, drug
allergies and intolerances, comorbid conditions, prior and
current microbiology results from aspirations and surgeries,
and antimicrobial therapy for the PJI including local antimi-
crobial therapy (C-III).
3. A test for sedimentation rate or C-reactive protein
(CRP) should be performed in all patients with a suspected PJI
when the diagnosis is not clinically evident. The combination
of an abnormal sedimentation rate and CRP seems to provide
the best combination of sensitivity and speciﬁcity (A-III).
4. A plain radiograph should be performed in all patients
with suspected PJI (A-III).
5. A diagnostic arthrocentesis should be performed in all
patients with suspected acute PJI unless the diagnosis is
evident clinically and surgery is planned and antimicrobials
can be safely withheld prior to surgery. Arthrocentesis is also
advised in patients with a chronic painful prosthesis in whom
there is an unexplained elevated sedimentation rate or CRP
level (A-III) or in whom there is a clinical suspicion of PJI. It
may not be necessary if in this situation surgery is planned
and the result is not expected to alter management. Synovial
ﬂuid analysis should include a total cell count and differential
leukocyte count, as well as culture for aerobic and anaerobic
organisms (A-III). A crystal analysis can also be performed if
clinically indicated.
6. In PJI where the patient is medically stable, withholding
antimicrobial therapy for at least 2 weeks prior to collection of
synovial ﬂuid for culture increases the likelihood of recovering
an organism (B-III).
7. Blood cultures for aerobic and anaerobic organisms
should be obtained if fever is present, there is an acute onset
of symptoms, or if the patient has a condition or suspected
condition or concomitant infection or pathogen (eg Staphylo-
coccus aureus) that would make the presence of a bloodstream
infection more likely (B-III).
8. Imaging studies such as bone scans, leukocyte scans,
magnetic resonance imaging, computed tomography, and pos-
itron emission tomography scans should not be routinely used
to diagnose PJI (B-III).
Intraoperative Diagnosis of PJI
9. Intraoperative histopathological examination of peripros-
thetic tissue samples is a highly reliable diagnostic test provid-
ed that a pathologist skilled in interpretation of periprosthetic
Table 1. Strength of Recommendation and Quality of Evidence
Category/Grade Definition
Strength of recommendation
A Good evidence to support a recommendation
for or against use.
B Moderate evidence to support a
recommendation for or against use.
C Poor evidence to support a recommendation.
Quality of evidence
I Evidence from >1 properly randomized,
controlled trial.
II Evidence from >1 well-designed clinical trial,
without randomization; from cohort or
case-controlled analytic studies (preferably
from >1 center); from multiple time-series; or
from dramatic results from uncontrolled
experiments.
III Evidence from opinions of respected
authorities, based on clinical experience,
descriptive studies, or reports of expert
committees.
Source: [5]. Adapted and reproduced with the permission of the Minister of
Public Works and Government Services Canada, 2009.
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tissue is available. It should be performed at the time of revi-
sion prosthetic joint surgery, when available, if the presence of
infection is in doubt based on the clinical suspicion of the
surgeon and the results will affect management, for example,
in deciding between revision arthroplasty and 2-stage
exchange (B-III).
10. At least 3 and optimally 5 or 6 periprosthetic intra-
operative tissue samples or the explanted prosthesis itself
Figure 1. Preoperative and intraoperative diagnosis of prosthetic joint infection. Abbrevation: CRP, C-reactive protein.
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should be submitted for aerobic and anaerobic culture at
the time of surgical debridement or prosthesis removal to
maximize the chance of obtaining a microbiologic diagnosis
(B-II).
11. When possible (see above), withholding antimicrobial
therapy for at least 2 weeks prior to collecting intraoperative
culture specimens increases the yield of recovering an organ-
ism (A-II).
Deﬁnition of PJI
12. The presence of a sinus tract that communicates with
the prosthesis is deﬁnitive evidence of PJI (B-III).
13. The presence of acute inﬂammation as seen on histo-
pathologic examination of periprosthetic tissue at the time of
surgical debridement or prosthesis removal as deﬁned by
the attending pathologist is highly suggestive evidence of PJI
(B-II).
14. The presence of purulence without another known etiolo-
gy surrounding the prosthesis is deﬁnitive evidence of PJI (B-III).
15. Two or more intraoperative cultures or combination of
preoperative aspiration and intraoperative cultures that yield
the same organism (indistinguishable based on common labo-
ratory tests including genus and species identiﬁcation or
common antibiogram) may be considered deﬁnitive evidence
of PJI. Growth of a virulent microorganism (eg, S. aureus) in
a single specimen of a tissue biopsy or synovial ﬂuid
may also represent PJI. One of multiple tissue cultures or a
single aspiration culture that yields an organism that is a
common contaminant (eg, coagulase-negative staphylococci,
Propionibacterium acnes) should not necessarily be considered
Figure 2. Management of prosthetic joint infection.
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evidence of deﬁnite PJI and should be evaluated in the context
of other available evidence (B-III).
16. The presence of PJI is possible even if the above criteria
are not met; the clinician should use his/her clinical judgment
to determine if this is the case after reviewing all the available
preoperative and intraoperative information (B-III).
II. What different surgical strategies should be considered for
treatment of a patient with PJI?
Recommendations
17. The ultimate decision regarding surgical management
should be made by the orthopedic surgeon with appropriate
consultation (eg, infectious diseases, plastic surgery) as neces-
sary (C-III).
18. Patients diagnosed with a PJI who have a well-ﬁxed
prosthesis without a sinus tract who are within approximately
30 days of prosthesis implantation or <3 weeks of onset of
infectious symptoms should be considered for a debridement
and retention of prosthesis strategy (Figure 2; A-II). Patients
who do not meet these criteria but for whom alternative surgi-
cal strategies are unacceptable or high risk may also be consid-
ered for a debridement and retention strategy, but relapse of
infection is more likely (B-III).
19. A 2-stage exchange strategy is commonly used in the
United States and is indicated in patients who are not candi-
dates for a 1-stage exchange who are medically able to
undergo multiple surgeries and in whom the surgeon believes
reimplantation arthroplasty is possible, based on the existing
soft tissue and bone defects (Figure 3; B-III). Obtaining a pre-
revision sedimentation rate and CRP is recommended by the
panel to assess the success of treatment prior to reimplanta-
tion (C-III). The panel believes that in selected circumstances
more than one 2-stage exchange if the ﬁrst attempt fails can
be successful (C-III).
20. A 1-stage or direct exchange strategy for the treatment of
PJI is not commonly performed in the United States but may be
considered in patients with a total hip arthroplasty (THA) infec-
tion who have a good soft tissue envelope provided that the
identity of the pathogens is known preoperatively and they are
susceptible to oral antimicrobials with excellent oral bioavailabil-
ity. There may be a greater risk of failure if bone grafting is
required and effective antibiotic impregnated bone cement
cannot be utilized (Figure 3; C-III).
21. Permanent resection arthroplasty may be considered in
nonambulatory patients; patients with limited bone stock,
poor soft tissue coverage, or infections due to highly resistant
organisms for which there is limited medical therapy; patients
with a medical condition precluding multiple major surgeries;
or patients who have failed a previous 2- stage exchange in
which the risk of recurrent infection after another staged ex-
change is deemed unacceptable (Figure 4; B-III).
22. Amputation should be the last option considered but may
be appropriate in selected cases. Except in emergent cases, refer-
ral to a center with specialist experience in the management of
PJI is advised before amputation is carried out (Figure 4; B-III).
III. What is the medical treatment for a patient with PJI
following debridement and retention of the prosthesis?
Recommendations
Staphylococcal PJI
23. Two to 6 weeks of a pathogen-speciﬁc intravenous anti-
microbial therapy (Table 2) in combination with rifampin
300–450 mg orally twice daily followed by rifampin plus a
Figure 3. Management of prosthetic joint infection—removal of prosthesis. Abbreviation: THA, total hip arthroplasty.
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companion oral drug for a total of 3 months for a THA infec-
tion and 6 months for a total knee arthroplasty (TKA) infec-
tion (A-I). Total elbow, total shoulder, and total ankle
infections may be managed with the same protocols as THA
infections (C-III). Recommended oral companion drugs for
rifampin include ciproﬂoxacin (A-I) or levoﬂoxacin (A-II).
Secondary companion drugs to be used if in vitro susceptibil-
ity, allergies, intolerances, or potential intolerances support
the use of an agent other than a quinolone include but are not
limited to co-trimoxazole (A-II), minocycline or doxycycline
(C-III), or oral ﬁrst-generation cephalosporins (eg, cephalex-
in) or antistaphylococcal penicillins (eg, dicloxacillin; C-III).
If rifampin cannot be used because of allergy, toxicity, or
intolerance, the panel recommends 4–6 weeks of pathogen-
speciﬁc intravenous antimicrobial therapy (B-III).
24. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
25. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with cephalexin, dicloxacillin, co-
trimoxazole, or minocycline based on in vitro susceptibility, al-
lergies, or intolerances (Table 3; B-III). Rifampin alone is not
recommended for chronic suppression, and rifampin combina-
tion therapy is not generally recommended. One member of
the panel uses rifampin combination therapy for chronic sup-
pression in selected situations (A. R. B.). The recommendation
regarding using suppressive therapy after rifampin treatment
was not unanimous (W. Z., D. L.). Clinical and laboratory mon-
itoring for efﬁcacy and toxicity is advisable. The decision to
offer chronic suppressive therapy must take into account the
individual circumstances of the patient including the ability to
Figure 4. Management of prosthetic joint infection when patients are not a candidate for new prosthesis. Abbreviations: TEA, total elbow arthro-
plasty; TKA, total knee arthroplasty.
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Table 2. Intravenous or Highly Bioavailable Oral Antimicrobial Treatment of Common Microorganisms Causing Prosthetic Joint Infection (B-III Unless Otherwise Stated in Text)
Microorganism Preferred Treatmenta Alternative Treatmenta Comments
Staphylococci, oxacillin-
susceptible
Nafcillinb sodium 1.5–2 g IV q4-6 h Vancomycin IV 15 mg/kg q12 h See recommended use of rifampin as a
companion drug for rifampin-susceptible
PJI treated with debridement and
retention or 1-stage exchange in text
or or
Cefazolin 1–2 g IV q8 h Daptomycin 6 mg/kg IV q 24 h
or or
Ceftriaxonec 1–2 g IV q24 h Linezolid 600 mg PO/IV every 12 h
Staphylococci, oxacillin-
resistant
Vancomycind IV 15 mg/kg q12 h Daptomycin 6 mg/kg IV q24 h
or
Linezolid 600 mg PO/IV q12 h
See recommended use of rifampin as a
companion drug for rifampin-susceptible
PJI treated with debridement and
retention or 1-stage exchange in text
Enterococcus spp,
penicillin-susceptible
Penicillin G 20–24 million units IV q24 h
continuously or in 6 divided doses
or
Ampicillin sodium 12 g IV q24 h
continuously or in 6 divided doses
Vancomycin 15 mg/kg IV q12 h
or
Daptomycin 6 mg/kg IV q24 h
4–6 wk. Aminoglycoside optional
Vancomycin should be used only in case
of penicillin allergy
or
Linezolid 600 mg PO or
IV q12 h
Enterococcus spp,
penicillin-resistant
Vancomycin 15 mg/kg IV q12 h Linezolid 600 mg PO or
IV q12 h
or
Daptomycin 6 mg IV q24 h
4–6 wk. Addition of aminoglycoside optional
Pseudomonas aeruginosa Cefepime 2 g IV q12 h Ciprofloxacin 750 mg PO bid 4–6 wk
or or 400 mg IV q12 h Addition of aminoglycoside optional
Meropeneme 1 g IV q8 h or Use of 2 active drugs could be considered
based on clinical circumstance of patient.
If aminoglycoside in spacer, and organism
aminoglycoside susceptible than double
coverage being provided with
recommended IV or oral monotherapy
Ceftazidime 2 g IV q8 h
Enterobacter spp Cefepime 2 g IV q12 h
or
Ertapenem 1 g IV q24 h
Ciprofloxacin 750 mg PO
or 400 mg IV q12 h
4–6 wk.
Enterobacteriaceae IV β-lactam based on in vitro susceptibilities
or
Ciprofloxacin 750 mg PO bid
4–6 wk
β-hemolytic streptococci Penicillin G 20–24 million units IV q24 h
continuously or in 6 divided doses
or
Ceftriaxone 2 g IV q24 h
Vancomycin 15 mg/kg IV q12 h 4–6 wk
Vancomycin only in case of allergy
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use rifampin in the initial phase of treatment, the potential for
progressive implant loosening and loss of bone stock, and the
hazards of prolonged antibiotic therapy; it is therefore generally
reserved for patients who are unsuitable for, or refuse, further
exchange revision, excision arthroplasty, or amputation.
PJI Due to Other Organisms
26. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy (Table 2; B-II).
27. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
28. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimens (Table 3) based on in vitro sensitiv-
ities, allergies, and intolerances (B-III). Chronic suppression
after ﬂuoroquinolone treatment of PJI due to gram-negative
bacilli was not unanimously recommended (W. Z., D. L.).
Clinical and laboratory monitoring for efﬁcacy and toxicity is
advisable. Similar considerations regarding hazards and effec-
tiveness apply to those above.
IV. What is the medical treatment for a patient with PJI
following resection arthroplasty with or without planned staged
reimplantation?
Recommendations
29. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
30. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
V. What is the medical treatment for a patient with PJI
following 1-stage exchange?
Recommendations
Staphylococcal PJI
31. Two to 6 weeks of pathogen-speciﬁc intravenous anti-
microbial therapy in combination with rifampin 300–450 mg
orally twice daily followed by rifampin plus a companion oral
drug for a total of 3 months is recommended (Table 2; C-III).
Recommended oral companion drugs for rifampin include
ciproﬂoxacin (A-I) or levoﬂoxacin (A-II). Secondary compan-
ion drugs to be used if in vitro susceptibility, allergies, intoler-
ances, or potential intolerances support the use of an agent
other than a quinolone include but are not limited to co-tri-
moxazole (A-II), minocycline or doxycycline (B-III), or oral
ﬁrst-generation cephalosporins (eg, cephalexin) or antistaphy-
lococcal penicillins (eg, dicloxacillin; C-III). If rifampin
cannot be used because of allergy, toxicity, or intolerance,
than the panel recommends 4–6 weeks of pathogen-speciﬁc
intravenous antimicrobial therapy.Ta
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32. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
33. Indeﬁnite chronic oral antimicrobial suppression may
follow the above regimen with either cephalexin, dicloxacillin,
co-trimoxazole, or minocycline or doxycycline based on in
vitro susceptibility, allergies, or intolerances (Table 3; B-III).
Rifampin alone is not recommended for chronic suppression,
and rifampin combination therapy is also not generally rec-
ommended. One member of the panel uses rifampin combina-
tion therapy for chronic suppression in selected situations
(A. R. B.). The recommendation regarding using suppressive
therapy after rifampin treatment was not unanimous (D. L.,
W. Z.). Clinical and laboratory monitoring for efﬁcacy and
toxicity is advisable. The decision to offer chronic suppressive
therapy must take into account the individual circumstances
of the patient including the ability to use rifampin in the
initial phase of treatment, the potential for progressive
implant loosening and loss of bone stock, and the hazards of
prolonged antibiotic therapy; it is therefore generally reserved
for patients who are unsuitable for, or refuse, further exchange
revision, excision arthroplasty, or amputation.
PJI Due to Other Organisms
34. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
(Table 2; A-II).
35. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
36. Indeﬁnite chronic oral antimicrobial suppression
should follow regimens in Table 3 and be based on in vitro
sensitivities, allergies, and intolerances (B-III). Chronic sup-
pression after ﬂuoroquinolone treatment of gram-negative
bacilli was not unanimously recommended (D. L., W. Z.).
Clinical and laboratory monitoring for efﬁcacy and toxicity
is advisable. Similar considerations regarding hazards and
effectiveness apply to those above.
VI. What is the medical treatment for a patient with PJI
following amputation?
37. Pathogen-speciﬁc antimicrobial therapy should be
given until 24–48 hours after amputation assuming all infected
bone and soft tissue has been surgically removed and there
is no concomitant sepsis syndrome or bacteremia. If sepsis
syndrome or bacteremia are present, treatment duration is
to be according to recommendations for these syndromes
(C-III).
38. Four to 6 weeks of pathogen-speciﬁc intravenous or
highly bioavailable oral antimicrobial therapy is recommended
if, despite surgery, there is residual infected bone and soft
tissue (ie, hip disarticulation for THA infection, long-stem
TKA prosthesis where the prosthesis extended above the level
of amputation; Table 2; C-III).
Table 3. Common Antimicrobials Used for Chronic Oral Antimicrobial Suppression (B-III Unless Otherwise Stated in Text)a,b
Microorganism Preferred Treatment Alternative Treatment
Staphylococci, oxacillin-susceptible Cephalexin 500 mg PO tid or qid
or
Cefadroxil 500 mg PO bid
Dicloxacillin 500 mg PO tid or qid
Clindamycin 300 mg PO qid
Amoxicillin-clavulanate 500 mg PO tid
Staphylococci, oxacillin-resistant Cotrimoxazole 1 DS tab PO bid
Minocycline or doxycycline100 mg PO bid
β-hemolytic streptococci Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Cephalexin 500 mg PO tid or qid
Enterococcus spp, penicillin susceptible Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Pseudomonas aeruginosa Ciprofloxacin 250–500 mg PO bid
Enterobacteriaceae Cotrimoxazole 1 DS tab PO bid β-lactam oral therapy based on in vitro
susceptibilities
Propionibacterium spp Penicillin V 500 mg PO bid to qid
or
Amoxicillin 500 mg PO tid
Cephalexin 500 mg PO tid or qid
Minocycline or doxycycline 100 mg PO
bid
Abbreviations: bid, twice daily; DS, double strength; PO, per oral; qid, 4 times daily; tid, 3 times daily.
a Antimicrobial dosage needs to be adjusted based on patients’ renal and hepatic function. Antimicrobials should be chosen based on in vitro susceptibility as
well as patient drug allergies, intolerances, and potential drug interactions or contraindications to a specific antimicrobial.
b Clinical and laboratory monitoring for efficacy and safety should occur based on the clinical judgment of the clinician caring for the patient. The possibility of
prolonged QTc interval and tendinopathy should be discussed and monitored when using fluoroquinolones. The possibility of Clostridium difficile colitis should
also be discussed when using any antimicrobial.
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39. Monitoring of outpatient intravenous antimicrobial
therapy should follow published guidelines (A-II) [6].
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